Psych Vivas · Psychopharmacology — long-acting injectable antipsychotics
Long-acting injectable antipsychotics — consultant viva
Fellowship viva covering LAI indications, agent map, initiation rules, evidence ladder, PDSS, and clozapine boundary.
On this page
Study tools
Target exams
FRANZCPMRCPsychABPNMD-DNB
Prompt
Examiner places cards: oral overlap, PP1M day 1+8, PDSS, PRELAPSE, Tiihonen HR 0.36, Rosenheck negative RCT, TRRIP vs LAI, CTO injection.
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect agent-specific initiation rules, named trials, and ethical framing of injectables without inventing exact local milligram tables as universal law.[3][4]
References8ShowHide
- [1]Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia Am J Psychiatry, 2011.PMID 21362741
- [2]Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia JAMA Psychiatry, 2017.PMID 28593216
- [3]Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies Lancet Psychiatry, 2021.PMID 33862018
- [4]Kane JM, Schooler NR, Marcy P, et al. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial JAMA Psychiatry, 2020.PMID 32667636
- [5]Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia N Engl J Med, 2011.PMID 21366475
- [6]Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia J Clin Psychiatry, 2008.PMID 18452346
- [7]Berwaerts J, Liu Y, Gopal S, et al. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial JAMA Psychiatry, 2015.PMID 25820612
- [8]Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology Am J Psychiatry, 2017.PMID 27919182